Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9378(91)91460-e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurobrucellosis: a retrospective cohort of 106 patients.
Trop Med Health
January 2025
Department of Community Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Background: Neurobrucellosis, a serious central nervous system infection caused by Brucella species, presents significant challenges due to its diverse clinical manifestations and the risk of long-term complications and poor outcomes. Identifying predictors of adverse outcomes is critical for improving patient management and overall prognosis.
Objectives: This study aimed to evaluate the long-term morbidity and mortality associated with neurobrucellosis and to identify key predictors of adverse outcomes.
Effects of modified reverse sural neurocutaneous flap repair on wound healing in patients with soft tissue defects of the foot and ankle.
J Orthop Surg Res
January 2025
Operation Room, Hunan University of Medicine General Hospital, No. 144, Jinxi South Road, Huaihua City, Hunan Province, 418000, China.
Objective: The surgical team in this study examined the efficacy of a modified reverse sural neurocutaneous flap repair in treating soft tissue defects of the ankle and foot caused by accidents.
Methods: This study enrolled 89 patients treated for soft tissue defects of the ankle or foot between January 2007 and December 2023. The patients were divided into two groups: 44 patients underwent a modified reverse sural neurocutaneous flap repair, while 45 received traditional treatment.
Interpreting positive celiac serology in children with new-onset type 1 diabetes.
J Pediatr Endocrinol Metab
January 2025
Division of Gastroenterology, Hepatology, & Nutrition, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
Objectives: The association of celiac disease (CD) in type 1 diabetes mellitus (T1DM) is well-established, yet variation exists in screening practices. This study measures the accuracy of early screening with tissue transglutaminase Immunoglobulin A (TTG-IgA) and endomysial antibody (EMA) in newly diagnosed T1DM.
Methods: This is a retrospective study of children with T1DM between 2013 and 2019 with early CD screening and follow-up.
Mortality in patients with Sjögren Disease: A Prospective Cohort Study Identifying Key Predictors.
J Rheumatol
January 2025
J. L. Andréu Sánchez, PhD, Rheumatology department, Puerta de Hierro Majadahonda University Hospital, Autonoma University, Madrid, Spain.
Objective: To quantify the mortality risk in a large, well-characterized cohort of Sjögren's disease (SjD) patients and to identify independent predictors of mortality in this population.
Methods: We included 314 patients diagnosed with SjD according to the 2002 American-European Consensus Group criteria from a prospective, multicenter SjögrenSER-PROS cohort. Detailed data on systemic manifestations, serological markers, disease activity, and mortality was collected after 9 years of follow up.
The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis.
Respir Med
January 2025
Hospital Costa del Sol, (Málaga), Marbella, Spain. Electronic address:
Background: The ORBE II study showed the real-world effectiveness of benralizumab in severe eosinophilic asthma (SEA). This subgroup analysis aimed to characterize patients and outcomes based on baseline blood eosinophil count (BEC) and/or fractional exhaled nitric oxide (FeNO) levels.
Methods: In this analysis of the ORBE II retrospective study, SEA patients receiving benralizumab were categorized into subgroups based on individual or combined BEC/FeNO levels, according to the following thresholds: high BEC (hiBEC): ≥300 cells/μL; low BEC (loBEC): <300 cells/μL; high FeNO (hiFeNO): ≥50 ppb; low FeNO (loFeNO): <50 ppb.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!